If you made any changes in Pure these will be visible here soon.

Research Output 1991 2019

  • 5610 Citations
  • 31 h-Index
  • 128 Article
  • 2 Review article
Filter
Article
Article
9 Citations (Scopus)

A 2-es típusú Janus tirozin kináz Val617Phe aktiváló pontmutáció szerepe és kimutatásának jelentosége myeloproliferatív szindrómában

Andrikovics, H., Szilvási, A., Meggyesi, N., Király, V., Halm, G., Lueff, S., Nahajevszky, S., Mikala, G., Sipos, A., Lovas, N., Csukly, Z., Mátrai, Z., Tamáska, J., Tordai, A. & Masszi, T., febr. 4 2007, In : Orvosi Hetilap. 148, 5, p. 203-210 8 p.

Research output: Article

Janus Kinase 2
Essential Thrombocythemia
Mutation
Polycythemia Vera
Primary Myelofibrosis
18 Citations (Scopus)

Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza

Gézsi, A., Budde, U., Deák, I., Nagy, E., Mohl, A., Schlammadinger, Á., Boda, Z., Masszi, T., Sadler, J. E. & Bodó, I., jún. 2010, In : Journal of Thrombosis and Haemostasis. 8, 6, p. 1273-1280 8 p.

Research output: Article

von Willebrand Diseases
von Willebrand Factor
Half-Life
Theoretical Models
Deamino Arginine Vasopressin
4 Citations (Scopus)

A csontvelô eredetû ôssejtek megjelenése az ép vastagbélhámban és a gyulladást követô hámregenerációban.

Valcz, G., Krenács, T., Sípos, F., Wichmann, B., Tóth, K., Leiszter, K., Balogh, Z., Csizmadia, A., Hagymási, K., Müzes, G., Masszi, T., Molnár, B. & Tulassay, Z., okt. 4 2009, In : Orvosi Hetilap. 150, 40, p. 1852-1857 6 p.

Research output: Article

Regeneration
Stem Cells
Epithelium
Bone Marrow
Inflammation
15 Citations (Scopus)

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients

Meggyesi, N., Kozma, A., Halm, G., Nahajevszky, S., Bátai, Á., Fekete, S., Barta, A., Ujj, G., Lueff, S., Sipos, A., Ádám, E., Bors, A., Reményi, P., Masszi, T., Tordai, A. & Andrikovics, H., dec. 2011, In : Acta Haematologica. 127, 1, p. 34-42 9 p.

Research output: Article

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosome Aberrations
Protein-Tyrosine Kinases
Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1 Citation (Scopus)

Akut szívizom-infarctusban végzett elso magyar autológ csontveloi ossejt transzplantációk során szerzett tapasztalataink

Vértesljai, M., Piróth, Z., Fontos, G., Tóth, A., Símor, T., Lueff, S., Reményi, P., Réti, M., Masszi, T. & Andréka, P., jan. 8 2006, In : Orvosi Hetilap. 147, 1, p. 3-6 4 p.

Research output: Article

Bone Marrow Transplantation
Stem Cells
Myocardial Infarction
Cell- and Tissue-Based Therapy
Bone Marrow Cells
7 Citations (Scopus)

Allogeneic bone marrow transplantation for acute leukaemia - IGCI experience

Labar, B., Masszi, T., Morabito, F., Mistrik, M., Holowiecki, J., Bogdaníc, V., Nemet, D., Mrsić, M., Krieger, O. & Lutz, D., jún. 1996, In : Bone Marrow Transplantation. 17, 6, p. 1009-1012 4 p.

Research output: Article

Homologous Transplantation
Bone Marrow Transplantation
Leukemia
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1 Citation (Scopus)

Allogeneic bone marrow transplantation for acute leukemia in adults

Masszi, T., Remenyi, P., Krivan, G., Goda, V. & Reti, M., 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4

Research output: Article

Homologous Transplantation
Bone Marrow Transplantation
Leukemia
Transplants
Mitobronitol
82 Citations (Scopus)

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., Volin, L., Poire, X., Aljurf, M., Masszi, T., Socie, G., Sengelov, H., Michallet, M., Passweg, J., Veelken, H., Yakoub-Agha, I., Shimoni, A. & Mohty, M., okt. 1 2013, In : Journal of Clinical Oncology. 31, 28, p. 3549-3556 8 p.

Research output: Article

Busulfan
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Blood Group Antigens
Acute Myeloid Leukemia
Peripheral Blood Stem Cell Transplantation
Bone Marrow Transplantation
Bone Marrow
Stem Cell Transplantation
Graft vs Host Disease

A myeloma multiplex bortezomibalapú kezelése: Hazai tapasztalatok az elso 60 beteg adatainak tükrében

Mikala, G., Árpád, B., Andrea, C., Zoltán, C., János, D., Gabriella, H., Judit, J., Balázs, K., Nóra, L., Sándor, L., Mónika, P., Péter, R., Andrea, S., Zsuzsanna, T. & Masszi, T., jan. 2007, In : Lege Artis Medicinae. 17, 1, p. 26-34 9 p.

Research output: Article

Multiple Myeloma
Therapeutics
Survival
Bortezomib
Salvage Therapy
18 Citations (Scopus)

An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary

Mohl, A., Marschalek, R., Masszi, T., Nagy, E., Obser, T., Oyen, F., Sallai, K., Bodó, I. & Schneppenheim, R., 2008, In : Journal of Thrombosis and Haemostasis. 6, 10, p. 1729-1735 7 p.

Research output: Article

Type 3 Von Willebrand's Disease
Hungary
von Willebrand Factor
von Willebrand Diseases
Genetic Recombination
5 Citations (Scopus)
Bone Marrow Transplantation
Keratinocytes
Tissue Donors
Biopsy
Skin

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, A., Chabannon, C., Masszi, T., Pohlreich, D., Scheid, C., Thieblemont, C., Wahlin, B. E., Sakellari, I., Russell, N., Janikova, A., Dabrowska-Iwanicka, A., Touzeau, C., Esquirol, A., Jantunen, E., van der Werf, S., Bosman, P., Boumendil, A., Liu, Q., Celanovic, M., Montoto, S. & 1 others, Dreger, P., jan. 1 2019, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Article

Granulocyte Colony-Stimulating Factor
Registries
Lymphoma
Transplantation
Bone Marrow
23 Citations (Scopus)
Adrenergic Receptors
Coronary Artery Disease
Blood Platelets
Adenosine Diphosphate
Epinephrine
72 Citations (Scopus)

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., jan. 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Article

Multiple Myeloma
Interleukin-6
Placebos
Disease-Free Survival
Dexamethasone
18 Citations (Scopus)

Apoptosis induction by retinoids in eosinophilic leukemia cells: Implication of retinoic acid receptor-α signaling in all-trans-retinoic acid hypersensitivity

Robert, C., Delva, L., Balitrand, N., Nahajevszky, S., Masszi, T., Chomienne, C. & Papp, B., jún. 15 2006, In : Cancer Research. 66, 12, p. 6336-6344 9 p.

Research output: Article

Hypereosinophilic Syndrome
Retinoic Acid Receptors
Retinoids
Tretinoin
Hypersensitivity
99 Citations (Scopus)

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Harousseau, J. L., Martinelli, G., Jedrzejczak, W. W., Brandwein, J. M., Bordessoule, D., Masszi, T., Ossenkoppele, G. J., Alexeeva, J. A., Beutel, G., Maertens, J., Vidriales, M. B., Dombret, H., Thomas, X., Burnett, A. K., Robak, T., Khuageva, N. K., Golenkov, A. K., Tothova, E., Mollgard, L., Park, Y. C. & 3 others, Bessems, A., De Porre, P. & Howes, A. J., 2009, In : Blood. 114, 6, p. 1166-1173 8 p.

Research output: Article

tipifarnib
Hydroxyurea
Acute Myeloid Leukemia
Survival
Therapeutics
57 Citations (Scopus)

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, de la Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., júl. 15 2016, (Accepted/In press) In : Leukemia.

Research output: Article

Multiple Myeloma
Cyclophosphamide
Adrenal Cortex Hormones
Confidence Intervals
Survival
1 Citation (Scopus)

Autologus blood/marrow transplantation. Autologous stem cell transplantation for malignant lymphomas

Remenyi, P., Masszi, T., Krivan, G., Goda, V. & Reti, M., 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4

Research output: Article

Stem Cell Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Lymphoma
Transplantation
173 Citations (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., aug. 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Article

Peripheral T-Cell Lymphoma
Disease-Free Survival
Drug Approval
Histone Deacetylase Inhibitors
belinostat
6 Citations (Scopus)

Bone marrow transplantation in non-malignant disorders

Krivan, G., Timar, L., Goda, V., Reti, M., Remenyi, P. & Masszi, T., 1998, In : Bone Marrow Transplantation. 22, SUPPL. 4

Research output: Article

Bone Marrow Transplantation
Mucolipidoses
Mucopolysaccharidosis I
Transplants
Fanconi Anemia
16 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., nov. 1 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Article

Thalidomide
Multiple Myeloma
Cyclophosphamide
Dexamethasone
Residual Neoplasm
66 Citations (Scopus)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Gambacorti-Passerini, C., Brümmendorf, T. H., Kim, D. W., Turkina, A. G., Masszi, T., Assouline, S., Durrant, S., Kantarjian, H. M., Khoury, H. J., Zaritskey, A., Shen, Z. X., Jin, J., Vellenga, E., Pasquini, R., Mathews, V., Cervantes, F., Besson, N., Turnbull, K., Leip, E., Kelly, V. & 1 others, Cortes, J. E., 2014, In : American Journal of Hematology. 89, 7, p. 732-742 11 p.

Research output: Article

Leukemia, Myeloid, Chronic Phase
Safety
Cytogenetics
Therapeutics
src-Family Kinases
312 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., máj. 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Article

Stem Cell Transplantation
Hodgkin Disease
Placebos
Recurrence
Disease-Free Survival
1 Citation (Scopus)

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., jan. 1 2019, (Accepted/In press) In : Pathology.

Research output: Article

Calreticulin
Immunohistochemistry
Mutation
Neoplasms
Essential Thrombocythemia
613 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, jan. 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Control Groups
Disease-Free Survival
Confidence Intervals
353 Citations (Scopus)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., jan. 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Multicenter Studies
Intravenous Infusions
Random Allocation
20 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., jan. 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Article

Multiple Myeloma
Dexamethasone
Thalidomide
Disease-Free Survival
Therapeutics
57 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., szept. 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Article

Multiple Myeloma
Cytogenetics
Disease-Free Survival
Dexamethasone
carfilzomib
23 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., aug. 1 2016, In : European Journal of Haematology. 97, 2, p. 192-200 9 p.

Research output: Article

Polycythemia Vera
Quality of Life
Symptom Assessment
Hydroxyurea
Pruritus
19 Citations (Scopus)

Characterization and function of histamine receptors in human bone marrow stromal cells

Nemeth, K., Wilson, T., Rada, B., Parmelee, A., Mayer, B., Búzás, E., Falus, A., Key, S., Masszi, T., Kárpáti, S. & Mezey, E., febr. 2012, In : Stem Cells. 30, 2, p. 222-231 10 p.

Research output: Article

Histamine Receptors
Mesenchymal Stromal Cells
Histamine
Interleukin-6
Artificial Cells
6 Citations (Scopus)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational Biology
Molecular Biology
Exons
Clonal Evolution
9 Citations (Scopus)

Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin

Skribek, H., Otvos, R., Flaberg, E., Nagy, N., Markasz, L., Eksborg, S., Masszi, T., Kozma, A., Adam, E., Miseta, A., Klein, E. & Szekely, L., dec. 2010, In : Experimental Hematology. 38, 12, p. 1219-1230 12 p.

Research output: Article

Lymphoid Leukemia
Epirubicin
Daunorubicin
Prednisolone
Doxorubicin
24 Citations (Scopus)

CIDP cured by allogeneic hematopoietic stem cell transplantation [1]

Reményi, P., Masszi, T., Borbényi, Z., Soós, J., Siklós, L. & Engelhardt, J., aug. 2007, In : European Journal of Neurology. 14, 8

Research output: Article

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Aplastic Anemia
Hematopoietic Stem Cell Transplantation
Alopecia
Homologous Transplantation
8 Citations (Scopus)

Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population

Mohl, A., Boda, Z., Jager, R., Losonczy, H., Marosi, A., Masszi, T., Nagy, E., Nemes, L., Obser, T., Oyen, F., Radványi, G., Schlammadinger, Á., Szélessy, Z. S., Várkonyi, A., Vezendy, K., Vilimi, B., Schneppenheim, R. & Bodó, I., máj. 2011, In : Journal of Thrombosis and Haemostasis. 9, 5, p. 945-952 8 p.

Research output: Article

Type 3 Von Willebrand's Disease
Isoantibodies
Gene Deletion
von Willebrand Factor
Mutation
6 Citations (Scopus)

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., jún. 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Article

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unrelated Donors
Leukemia
Tissue Donors
1 Citation (Scopus)

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Harrison, C. N., Griesshammer, M., Miller, C., Masszi, T., Passamonti, F., Zachee, P., Durrant, S., Pane, F., Guglielmelli, P., Verstovsek, S., Jones, M. M., Hunter, D. S., Sun, W., Li, J., Khan, M., Habr, D. & Kiladjian, J. J., jan. 1 2017, (Accepted/In press) In : British Journal of Haematology.

Research output: Article

Polycythemia Vera
INCB018424
13 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., jan. 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Article

Telomerase
Neoplasms
Therapeutics
Janus Kinase 2
Polycythemia Vera
2 Citations (Scopus)

Csontvelo-transzplantáció az imatinib korszakban

Masszi, T., 2005, In : Orvosi Hetilap. 146, 18 SUPPL.1, p. 900-904 5 p.

Research output: Article

Stem Cell Transplantation
Patient Preference
Hematopoietic Stem Cell Transplantation
Decision Making
Therapeutics
1 Citation (Scopus)

Csontveló-transzplantációs program Magyarországon: beszámoló az 1990-1995 közötti idószakról.

Petrányi, G., Masszi, T., Tímár, L., Kriván, G., Pálóczi, K., Nagy, K., Fekete, S., Reményi, P., Torbágyi, E., Dénes, R. & Kelemen, E., okt. 6 1996, In : Orvosi Hetilap. 137, 40, p. 2203-2208 6 p.

Research output: Article

Hungary
Bone Marrow Transplantation
Homologous Transplantation
Aplastic Anemia
Autologous Transplantation
473 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., aug. 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Disease-Free Survival
Control Groups
Neutropenia
87 Citations (Scopus)

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

Saglio, G., Hochhaus, A., Goh, Y. T., Masszi, T., Pasquini, R., Maloisel, F., Erben, P., Cortes, J., Paquette, R., Bradley-Garelik, M. B., Zhu, C. & Dombret, H., aug. 15 2010, In : Cancer. 116, 16, p. 3852-3861 10 p.

Research output: Article

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Dasatinib
Philadelphia Chromosome
319 Citations (Scopus)

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial

Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., Hellmann, A., Zaritsky, A., Golenkov, A., Radich, J., Hughes, T., Countouriotis, A. & Shah, N., jún. 15 2007, In : Blood. 109, 12, p. 5143-5150 8 p.

Research output: Article

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Hazards
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Diffusion Magnetic Resonance Imaging
Plasmacytoma
Subclavian Artery
Multiple Myeloma
Neoplasms
60 Citations (Scopus)

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Andrikovics, H., Krahling, T., Balassa, K., Halm, G., Bors, A., Koszarska, M., Batai, A., Dolgos, J., Csomor, J., Egyed, M., Sipos, A., Remenyi, P., Tordai, A. & Masszi, T., júl. 1 2014, In : Haematologica. 99, 7, p. 1184-1190 7 p.

Research output: Article

Calreticulin
Janus Kinase 2
Essential Thrombocythemia
Mutation
Primary Myelofibrosis
1 Citation (Scopus)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., jan. 1 2019, In : PloS one. 14, 6, e0218945.

Research output: Article

Open Access
Transplants
Hematologic Neoplasms
Stem cells
cell transplantation
Tissue Donors
10 Citations (Scopus)

Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy

Vertesaljai, M., Piroth, Z., Fontos, G., Andreka, G., Font, G., Szantho, G., Lueff, S., Reti, M., Masszi, T., Ablonczy, L., Juhasz, E. D., Símor, T., Turner, M. S. & Andréka, P., jún. 2008, In : Heart Failure Reviews. 13, 2, p. 227-244 18 p.

Research output: Article

Transfer Factor
Cell- and Tissue-Based Therapy
Stem Cells
Myocardial Infarction
Pharmaceutical Preparations
28 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., Le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., febr. 22 2018, (Accepted/In press) In : Journal of Cancer Research and Clinical Oncology. p. 1-10 10 p.

Research output: Article

Leukemia, Myeloid, Chronic Phase
Therapeutics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Progression
6 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., jan. 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Article

Stem Cell Transplantation
Multiple Myeloma
Interferons
Maintenance
Disease-Free Survival
Graft vs Host Disease
Steroids
Therapeutics
Inferior Mesenteric Artery
Superior Mesenteric Artery